» Articles » PMID: 37244844

Which Factors Predict Parametrial Involvement in Stage IB Cervical Cancer? A Chinese Multicentre Study

Overview
Publisher Elsevier
Date 2023 May 27
PMID 37244844
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To explore the clinicopathological risk factors influencing parametrial involvement (PI) in stage IB cervical cancer patients and compare the oncological outcomes between Q-M type B radical hysterectomy (RH) group and Q-M type C RH group.

Methods: Univariate and multivariate analyses were performed to explore the clinicopathological factors related to PI. Overall survival (OS) and disease-free survival (DFS) in patients with stage IB cervical cancer who underwent Q-M type B or Q-M type C RH under different circumstances of PI were also compared before and after propensity score matching (1:1 matching).

Results: A total of 6358 patients were enrolled in this study. Depth of stromal invasion>1/2 (HR: 3.139, 95% CI: 1.550-6.360; P = 0.001), vaginal margin (+) (HR: 4.271, 95% CI: 1.368-13.156; P = 0.011), lymphovascular space invasion (LVSI) (+) (HR: 2.238, 95% CI: 1.353-3.701; P = 0.002) and lymph node metastases (HR: 5.173, 95% CI: 3.091-8.658; P < 0.001) were associated with PI. Among the 6273 patients with negative PI, those in the Q-M type B RH group had a higher 5-year OS and DFS than those in the Q-M type C RH group before and after 1:1 matching. Among the 85 patients with positive PI, Q-M type C RH showed no survival benefits before and after 1:1 matching.

Conclusion: Stage IB cervical cancer patients with no lymph node metastasis, LVSI(-) and depth of stromal invasion ≤1/2 may be considered for Q-M type B radical hysterectomy.

Citing Articles

A Multicenter Study on the Relationship of Tumor Lesion Location with Bilateral Parametrial Involvement and Pelvic Lymph Node Metastasis in Cervical Squamous Cell Carcinoma.

Tang X, Yang B, Bian W, Li K, Pan S, Zhu W Ann Surg Oncol. 2025; .

PMID: 39863803 DOI: 10.1245/s10434-024-16802-8.


Peptidylarginine Deiminase Type 2 Predicts Tumor Progression and Poor Prognosis in Patients with Curatively Resected Biliary Tract Cancer.

Lin H, Yu C, Chi C, Wei C, Yin W, Tseng C Cancers (Basel). 2023; 15(16).

PMID: 37627159 PMC: 10452823. DOI: 10.3390/cancers15164131.